Medicare Drug Talks Risk Fewer New Cures, Industry Analysts Caution

As Medicare’s price-negotiation program expanded to 30 additional drugs this week, industry analysts renewed a warning that is harder to see than the savings: medicines that will never be developed because the revenue that would have funded them has been negotiated away.

The concern centers on the program’s design. Small-molecule drugs face negotiation nine years after approval — a window critics say punishes exactly the post-approval research that finds new uses for existing medicines. Two major manufacturers have publicly shelved development programs for additional indications, citing the negotiation timeline in investor filings.

Venture funding tells a similar story, skeptics argue. Early-stage investment in small-molecule startups has fallen 23 percent since the program’s enactment, while biologics — which get thirteen years before negotiation — have gained share. "Capital reads statutes," said Rena Aldous of the Whitfield Center for Medical Innovation. "It is flowing toward whatever the law disfavors least."

Program defenders dispute the causal chain, noting that small-molecule funding declines track a broader venture pullback and that overall pharmaceutical R&D spending hit a record last year. The Congressional Budget Office’s estimate remains that negotiation will reduce new drug approvals by a comparatively small number over thirty years.

The policy question both sides circle is calibration, not abolition — even most industry economists concede negotiation is now permanent. Proposals with traction include equalizing the small-molecule and biologic timelines and exempting new indications from the negotiation clock, changes that would trade some savings for pipeline insurance.